Insider Selling: Chemed (NYSE:CHE) CEO Sells 2,000 Shares of Stock

Key Points

• CEO Kevin McNamara sold 2,000 shares on May 1 at an average price of $421.13 for proceeds of $842,260, leaving him with 90,219 shares (a 2.17% reduction in his holding).
• Chemed recently beat EPS expectations but revenue slightly missed, reporting $5.65 EPS vs. $5.30 est; the company set FY2026 guidance of $24.00–$24.75 EPS, has a market cap of $5.66 billion and a $0.60 quarterly dividend (0.6% yield).

Chemed Corporation (NYSE:CHE - Get Free Report) CEO Kevin Mcnamara sold 2,000 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the sale, the chief executive officer owned 90,219 shares in the company, valued at $37,993,927.47. The trade was a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Chemed Trading Up 1.0%

NYSE:CHE traded up $4.29 during midday trading on Monday, hitting $426.45. 111,569 shares of the company traded hands, compared to its average volume of 236,435. The firm's fifty day moving average is $399.29 and its 200-day moving average is $425.94. Chemed Corporation has a 12-month low of $365.20 and a 12-month high of $583.96. The firm has a market capitalization of $5.66 billion, a P/E ratio of 23.24, a P/E/G ratio of 1.58 and a beta of 0.54. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11.

Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, beating the consensus estimate of $5.30 by $0.35. The company had revenue of $657.51 million for the quarter, compared to the consensus estimate of $659.22 million. Chemed had a return on equity of 27.18% and a net margin of 10.23%.Chemed's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.63 EPS. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. On average, sell-side analysts predict that Chemed Corporation will post 22.3 EPS for the current year.

Chemed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 13th. Shareholders of record on Monday, February 23rd were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, February 23rd. Chemed's dividend payout ratio is 13.08%.

Hedge Funds Weigh In On Chemed

A number of hedge funds and other institutional investors have recently made changes to their positions in CHE. Geneos Wealth Management Inc. grew its position in shares of Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company's stock worth $61,000 after buying an additional 76 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Chemed by 67.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company's stock worth $5,534,000 after buying an additional 4,560 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Chemed during the 2nd quarter worth $579,000. Brown Advisory Inc. grew its position in shares of Chemed by 36.9% during the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company's stock worth $267,000 after buying an additional 148 shares in the last quarter. Finally, Cerity Partners LLC grew its position in shares of Chemed by 237.7% during the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company's stock worth $2,165,000 after buying an additional 3,133 shares in the last quarter. Institutional investors own 95.85% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Jefferies Financial Group downgraded Chemed from a "buy" rating to a "hold" rating in a research report on Thursday, January 22nd. Wall Street Zen raised Chemed from a "hold" rating to a "buy" rating in a research report on Saturday. Oppenheimer cut their price objective on Chemed from $580.00 to $500.00 and set an "outperform" rating on the stock in a research report on Friday, February 27th. Zacks Research raised Chemed from a "strong sell" rating to a "hold" rating in a research report on Monday, April 27th. Finally, Royal Bank Of Canada upped their price objective on Chemed from $422.00 to $436.00 and gave the company a "sector perform" rating in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $501.50.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.